Nuvectis Pharma, Inc. - Common Stock (NVCT)

FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter’s option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.

FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium.

Nuvectis Pharma (NASDAQNVCT) has shared promising interim data from its Phase 1b study of NXP800, a drug candidate for treating platinum-resistant, ARID1a-mutated ovarian cancer. This patient population faces limited treatment options, and any indication of tumor stability or reduction is significant. The latest results reveal that NXP800, as a single-agent therapy, has led to stable disease in six patients and an unconfirmed partial response in one patient, which includes some cases of tumor shrinkage. These findings indicate that NXP800's effect even at a reduced dose, pointing to its potential as a potential therapeutic option in this challenging cancer subtype.

Nuvectis Pharma (NASDAQNVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors in NSCLC cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib (marketed by Roche) and lorlatinib (marketed by Pfizer). Meanwhile, NXP800, the company's GCN2 activator, is progressing in a Phase 1b trial targeting platinum resistant, ARID1a-mutated ovarian cancer, with a data update expected soon. This pipeline of innovative candidates has positioned Nuvectis at the forefront of precision oncology, and the market appears to be starting to take more notice as the company approaches important clinical milestones. Please refer to the disclaimers and disclosures also linked at the end of the report which it is subject to. Nothing contained herein is intended to serve as financial or investment advice.

Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics (October 23-25, 2024, Barcelona, Spain).

Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY.

Summit Therapeutics’ Breakthrough with Ivonescimab

Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

Nuvectis Pharma (NASDAQNVCT) continues to affirm its position as a trailblazer in precision oncology, as highlighted in their Q2 2024 financial results and business updates. The company's steadfast commitment to developing targeted therapies for unmet medical needs, coupled with prudent financial management, paints a promising picture for the months ahead.

A recently published market report showcases how the precision medicine market in the United States is on the brink of a remarkable expansion, with projections estimating its size to surge from USD 24.95 billion in 2023 to an astounding USD 76.12 billion by 2033. This astounding growth trajectory, with a CAGR of 11.80%, highlights the unique potential of precision medicine in disrupting healthcare. Amidst this changing landscape, Nuvectis Pharma (NASDAQNVCT) stands out as a unique and innovative player that may capitalize on the burgeoning market opportunities.

In the ever-evolving landscape of biotechnology, mergers and acquisitions (M&A) are emerging as pivotal mechanisms driving strategic realignments and innovative endeavors. A closer examination of these trends not only unveils the dynamic nature of the industry but also sheds light on the transformative potential of precision medicine. This article delves deep into the evolving paradigm of biotech M&A, with a focused lens on the burgeoning field of precision medicine and its profound implications for industry growth.

Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, California. Presentation details are below:

FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:

Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA).

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:

Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQNVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 11-15, 2023 Boston, MA).